A Phase I/II Trial of Panobinostat in Combination with Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma

Conclusion: Although the combination of panobinostat and lenalidomide appears safe in patients with relapsed/refractory HL, the limited efficacy and significant rates of neutropenia and febrile neutropenia observed do not support further evaluation of this combination in HL. This trial was registered at clinicaltrials.gov #NCT01460940. Teaser Based on previous studies demonstrating single agent efficacy with lenalidomide and panobinostat in patients with relapsed or refractory Hodgkin lymphoma (HL), we conducted a phase I/II study to evaluate the safety and efficacy of the combination in this patient population. The recommended phase 2 dose was 25 mg lenalidomide days 1-21 with 15 mg panobinostat TIW, and an ORR of 16.7% in patients was observed, with a durable response in one patient with lymphocyte predominant HL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research